CareDx

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CareDx reports solid Q4 earnings, eyes profitable growth in 2023

CareDx delivered strong financial results, focusing on profitable growth and strategic initiatives to drive revenue and market leadership.
While facing challenges such as fluctuating transplant volumes and market risks, the company is actively pursuing opportunities for expansion and innovation.
Overall, CareDx's performance, strengths, and proactive approach to challenges and opportunities position it for continued success and growth in the coming year.

CareDx reports Q1 2023 operational success amidst billing challenges

CareDx faced billing challenges impacting Medicare reimbursement but maintained strong operational performance and financial profile. The company is focused on mitigating financial impacts, managing cash flow, and pursuing growth opportunities through new modalities and publications.

CareDx reports Q2 revenue, faces Billing Article impact challenges

CareDx navigated challenges in Q2 2023 with a focus on financial strength, operational excellence, and strategic growth initiatives, despite a decline in Testing Services revenue.
The company's strong cash position, successful strategic executions, and pipeline catalysts position it well for future growth and expansion across Medicare and commercial plans.
While facing uncertainties and cost-saving initiatives, CareDx remains committed to achieving adjusted EBITDA positivity and overcoming challenges to drive long-term value for stakeholders.

CareDx reports solid Q3 earnings, eyes growth through expanded coverage

CareDx's Q3 2023 performance reflects revenue growth and improved EBITDA, driven by key business segments.
While facing challenges like CEO transition and payer coverage, the company is well-positioned for growth opportunities.
Strategic initiatives focusing on expanding coverage and driving testing volume growth indicate a positive outlook for CareDx.

CareDx surpasses revenue targets, eyes growth in transplant services

CareDx delivered strong financial performance in 2023, exceeding revenue guidance and focusing on strategic growth initiatives for 2024.
Despite facing challenges such as ongoing patent litigation and CEO search, the company is well-positioned to drive profitability and expand its offerings.
Opportunities for revenue growth exist in digital solutions, lab products, and transplant services, with potential catalysts for growth on the horizon.
CareDx's advocacy efforts and commercial expansions underscore its commitment to innovation and patient access in the transplant space.

CareDx reports robust Q1 earnings, raises guidance amidst market expansion

CareDx delivered strong financial results, showcasing growth across key business segments and improving EBITDA performance.
The company's focus on innovation, market expansion, and cost management positions it well for future growth and profitability.
With a solid cash position, positive clinical data, and expanded market coverage, CareDx is poised for continued success in the healthcare sector.

CareDx reports strong Q2 earnings, raises FY guidance confidently

CareDx delivered robust financial results in Q2 2024, driven by revenue growth, improved adjusted EBITDA, and successful validation studies for its diagnostic solutions.
The company's raised revenue guidance, expanding payer coverage, and planned Investor Day reflect a positive outlook and strategic focus on long-term growth.
While facing challenges in a competitive landscape, CareDx remains well-positioned to leverage opportunities in transplant diagnostics and healthcare innovation.
Investors can be optimistic about CareDx's performance, innovation pipeline, and strategic initiatives aimed at sustainable growth and market leadership.

CareDx reports robust Q3 earnings, targets $500M revenue by 2027

CareDx delivered strong financial performance in Q3 2024, driven by revenue growth, improved margins, and operational efficiencies.
The company's strategic initiatives to engage transplant centers and expand payer coverage have yielded positive results.
While facing challenges in operational execution and sustaining growth, CareDx remains optimistic about its future prospects and revenue targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CareDx (CDNA) delivered earnings and revenue surprises of -16.67% and 0.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved full year revenue of $321.8 million, an increase of 9% compared with full year 2021 revenue. Highest ever Q4 revenue of $82.

CareDx Reports Fourth Quarter and Full Year 2022 Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc.

CareDx Showcases Clinical Value of Multimodality and AI Innovation at the American Society of Transplantation Cutting Edge of Transplantation Meeting

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2022 after market close on Monday, February 27, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.

CareDx to Report Fourth Quarter and Full Year 2022 Financial Results

CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: CareDx (CDNA) Q4 Earnings Expected to Decline

CareDx Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions at the 2023 Tandem Meetings

Wilmington, Delaware--(Newsfile Corp. - February 14, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of CareDx, Inc. (NASDAQ: CDNA) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-caredx-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating CareDx, Inc.

BRISBANE, Calif.--( BUSINESS WIRE )--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Journal of the American College of Cardiology (JACC): Heart Failure has published a detailed guide 1 to help clinicians transition from routine invasive endomyocardial biopsy (EMB) to a less invasive acute rejection monitoring protocol in clinical practice.

JACC Publication Guides Use of CareDx's HeartCare Transplant Rejection Surveillance in Clinical Practice

BRISBANE, Calif.--( BUSINESS WIRE )--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced its leading participation and top spot, for the fourth consecutive year, as a Distinguished Founder's Circle Sponsor for the 23rd Annual ASTS (American Society of Transplant Surgeons) State of the Art Winter Symposium, taking place January 12-15, in Miami, Florida.

CareDx Fosters Transplant Innovation as Distinguished Founder's Circle Sponsor for the 23rd Annual American Society of Transplant Surgeons State of the Art Winter Symposium

BRISBANE, Calif.--( BUSINESS WIRE )--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported preliminary financial results for the fourth quarter and full year ended December 31, 2022.

CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022

BRISBANE, Calif.--( BUSINESS WIRE )--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication1 of new guidelines by the International Society for Heart and Lung Transplantation (ISHLT) supporting the use of CareDx's non-invasive molecular surveillance portfolio.

New ISHLT Guidelines Support Use of CareDx's HeartCare Solutions, AlloMap and AlloSure, in Routine Monitoring of Heart Transplant Patients

CDNA's share repurchase program will reduce outstanding shares by 8% based on current prices. This and management's short-term profitability ambitions warrant a rating upgrade. The company has a strong balance sheet, with enough dry powder to leverage itself into profitability as it gradually winds down its growth initiatives.

CareDx: What To Make Of The New Share Repurchase Program (Rating Upgrade)

BRISBANE, Calif.--( BUSINESS WIRE )--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that its Board of Directors has authorized a common stock repurchase program of up to $50 million of shares over a period of up to 24 months.

CareDx Announces $50 Million Stock Repurchase Program

BRISBANE, Calif.--( BUSINESS WIRE )--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the results of a new study published in Transplantation Direct1 which establishes a reference baseline when using AlloSure® Lung in the long-term surveillance of lung transplant patients.

Independent Prospective Study Defines Reference Range for CareDx's AlloSure for Long-Term Lung Transplant Surveillance

CareDx (CDNA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why CareDx (CDNA) Could be Great Choice for a Bottom Fisher

CareDx (CDNA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

CareDx (CDNA) Loses 22.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BRISBANE, Calif.--( BUSINESS WIRE )--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the five-year anniversary of AlloSure®, the groundbreaking, non-invasive donor-derived cell-free DNA (dd-cfDNA) surveillance solution used to measure allograft injury in solid organ transplant recipients. AlloSure along with AlloMap® represent disruptive innovations in the field of solid organ transplant.

CareDx Committed to Delivering Clinical Innovation to the Transplant Patient and Physician Community

CareDx To Participate in Upcoming Investor Conferences

CareDx, Inc (NASDAQ:CDNA ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Ian Cooney - VP, IR Reg Seeto - CEO Abhishek Jain - Interim CFO Conference Call Participants Brandon Couillard - Jefferies Operator Good day, ladies and gentlemen, and welcome to the CareDx, Incorporated Third Quarter 2022 Earnings Conference Call. Today's conference is being recorded.

CareDx, Inc. (CDNA) CEO Reg Seeto on Q3 2022 Results - Earnings Call Transcript

CareDx (CDNA) delivered earnings and revenue surprises of 57.14% and 2.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Reports Q3 Loss, Lags Revenue Estimates

CareDx Reports Third Quarter 2022 Results

CareDx Demonstrates Power of AlloSure and Digital Health Transplant Solutions at American Society of Nephrology Kidney Week

Independent Longitudinal Study Finds CareDx's AlloSure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients

CareDx Congratulates C-Path's Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System

News for CareDx Stock (CDNA)